Intervention/data | Visit 1 Initial screen | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | At time of UTI |
---|---|---|---|---|---|---|---|
Consent, baseline and randomisation | 3Â months | 6Â months | 9Â months | 12Â months | |||
Eligibility checklist | x | Â | Â | Â | Â | Â | Â |
Trial discussed and PIS given | x | Â | Â | Â | Â | Â | Â |
Informed consent | Â | x | Â | Â | Â | Â | Â |
UTI questionnaire | Â | x | x | x | x | x | x |
Adverse events | Â | Â | x | x | x | x | x |
SF-36 | Â | x | x | x | x | x | x |
Resource use questionnaire | Â | Â | x | x | x | x | Â |
Patient cost questionnaire | Â | Â | Â | Â | Â | x | Â |
Treatment satisfaction questionnaire | Â | Â | Â | Â | Â | x | Â |
Contingent valuation questionnaire | Â | Â | Â | Â | Â | x | Â |
Catheter specimens of urine (CSU) to central laboratory |  | x | x | x | x | x | x |
Perianal swab | Â | x | Â | x | Â | x | Â |
Creatinine (eGFR) and LFT | Â | x | Â | Â | Â | x | Â |